Is Acer Therapeutics Inc (NASDAQ:ACER) a Buy? The Stock Reported Less Sellers

June 16, 2018 - By Marie Mckinney

The stock of Acer Therapeutics Inc (NASDAQ:ACER) registered a decrease of 26.55% in short interest. ACER’s total short interest was 13,000 shares in June as published by FINRA. Its down 26.55% from 17,700 shares, reported previously. With 13,900 shares average volume, it will take short sellers 1 days to cover their ACER’s short positions.

The stock decreased 3.71% or $0.72 during the last trading session, reaching $18.7. About 18,330 shares traded or 39.88% up from the average. Acer Therapeutics Inc. (NASDAQ:ACER) has risen 171.45% since June 16, 2017 and is uptrending. It has outperformed by 158.88% the S&P500.

Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company has market cap of $140.20 million. The firm offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease . It currently has negative earnings. It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD).

Another recent and important Acer Therapeutics Inc. (NASDAQ:ACER) news was published by Globenewswire.com which published an article titled: “Report: Developing Opportunities within Opexa Therapeutics, Federated National Holding, Hess Midstream Partners …” on May 24, 2018.

Acer Therapeutics Inc. (NASDAQ:ACER) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: